Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges
Crinetics Pharmaceuticals (Nasdaq: CRNX) has launched ACRO/TRUTH, an educational initiative aimed at raising awareness about the challenges faced by acromegaly patients using current standard-of-care treatments. The initiative includes a website featuring patient testimonials and peer-reviewed data on treatment-related symptoms, side effects, and quality-of-life impacts.
The ACRO/TRUTH website provides authentic patient perspectives and clinical insights, addressing topics such as breakthrough symptoms, injection site reactions, and emotional impacts of treatment. It aims to improve communication between healthcare providers and patients, recognizing that patients may hesitate to discuss treatment challenges.
Developed with input from patient organizations like Acromegaly Community, ACRO/TRUTH seeks to empower patients and optimize treatment plans. The initiative will expand to include additional educational offerings, including a speaker's panel.
Crinetics Pharmaceuticals (Nasdaq: CRNX) ha lanciato ACRO/TRUTH, un'iniziativa educativa mirata ad aumentare la consapevolezza sulle sfide che affrontano i pazienti affetti da acromegalia che utilizzano i trattamenti standard attuali. L'iniziativa include un sito web con testimonianze di pazienti e dati sottoposti a revisione paritaria sui sintomi legati ai trattamenti, effetti collaterali e impatti sulla qualità della vita.
Il sito web di ACRO/TRUTH fornisce prospettive autentiche dei pazienti e approfondimenti clinici, affrontando temi come i sintomi di crisi, le reazioni nei siti di iniezione e gli impatti emotivi del trattamento. L'obiettivo è migliorare la comunicazione tra fornitori di assistenza sanitaria e pazienti, riconoscendo che i pazienti potrebbero esitare a discutere le sfide del trattamento.
Sviluppata con il contributo di organizzazioni di pazienti come Acromegaly Community, ACRO/TRUTH mira a dare potere ai pazienti e ottimizzare i piani di trattamento. L'iniziativa si espanderà per includere ulteriori offerte educative, tra cui un panel di relatori.
Crinetics Pharmaceuticals (Nasdaq: CRNX) ha lanzado ACRO/TRUTH, una iniciativa educativa destinada a aumentar la conciencia sobre los desafíos que enfrentan los pacientes con acromegalia que utilizan los tratamientos estándar actuales. La iniciativa incluye un sitio web con testimonios de pacientes y datos revisados por pares sobre los síntomas relacionados con el tratamiento, efectos secundarios y el impacto en la calidad de vida.
El sitio web de ACRO/TRUTH proporciona perspectivas auténticas de los pacientes y conocimientos clínicos, abordando temas como los síntomas de crisis, las reacciones en los sitios de inyección y los impactos emocionales del tratamiento. Su objetivo es mejorar la comunicación entre los proveedores de atención médica y los pacientes, reconociendo que los pacientes pueden dudar en discutir los desafíos del tratamiento.
Desarrollada con la contribución de organizaciones de pacientes como Acromegaly Community, ACRO/TRUTH busca empoderar a los pacientes y optimizar los planes de tratamiento. La iniciativa se expandirá para incluir ofertas educativas adicionales, incluyendo un panel de oradores.
Crinetics Pharmaceuticals (Nasdaq: CRNX)는 현재 표준 치료법을 사용하는 성장호르몬 과다분비증 환자들이 직면한 문제에 대한 인식을 높이기 위한 교육 이니셔티브인 ACRO/TRUTH를 출범했습니다. 이 이니셔티브는 치료 관련 증상, 부작용 및 삶의 질 영향에 대한 환자 증언 및 동료 검토 데이터를 포함하는 웹사이트를 포함합니다.
ACRO/TRUTH 웹사이트는 위기 증상, 주사 부위 반응 및 치료의 정서적 영향과 같은 주제를 다루며 환자들의 진정한 시각과 임상 통찰을 제공합니다. 이 사이트는 환자들이 치료 문제에 대해 논의하는 것을 주저할 수 있음을 인식하여 의료 제공자와 환자 간의 의사소통을 개선하는 것을 목표로 합니다.
제작은 Acromegaly Community와 같은 환자 조직의 의견을 반영하여 이루어졌으며, ACRO/TRUTH는 환자들에게 권한을 부여하고 치료 계획을 최적화할 수 있도록 합니다. 이 이니셔티브는 연사 패널을 포함하는 추가 교육 제공으로 확대될 것입니다.
Crinetics Pharmaceuticals (Nasdaq: CRNX) a lancé ACRO/TRUTH, une initiative éducative visant à sensibiliser aux défis rencontrés par les patients atteints d'acromégalie utilisant les traitements standard actuels. L'initiative comprend un site web présentant des témoignages de patients et des données validées par des pairs sur les symptômes liés au traitement, les effets secondaires et les impacts sur la qualité de vie.
Le site web ACRO/TRUTH fournit des perspectives authentiques de patients et des aperçus cliniques, abordant des sujets tels que les symptômes de crise, les réactions aux sites d'injection et les impacts émotionnels du traitement. L'objectif est d'améliorer la communication entre les professionnels de santé et les patients, en reconnaissant que ces derniers peuvent hésiter à discuter des défis liés aux traitements.
Développé avec l'apport d'organisations de patients comme Acromegaly Community, ACRO/TRUTH cherche à autonomiser les patients et à optimiser les plans de traitement. L'initiative s'élargira pour inclure des offres éducatives supplémentaires, y compris un panel de conférenciers.
Crinetics Pharmaceuticals (Nasdaq: CRNX) hat ACRO/TRUTH ins Leben gerufen, eine Bildungsinitiative, die darauf abzielt, das Bewusstsein für die Herausforderungen zu schärfen, mit denen Patienten mit Akromegalie konfrontiert sind, die derzeitige Standardbehandlungen verwenden. Die Initiative umfasst eine Website, die Patientenberichte und von Fachleuten geprüfte Daten zu behandlungsbezogenen Symptomen, Nebenwirkungen und Auswirkungen auf die Lebensqualität enthält.
Die ACRO/TRUTH-Website bietet authentische Patientenperspektiven und klinische Einblicke und behandelt Themen wie Durchbruchsymptome, Reaktionen an den Injektionsstellen und emotionale Auswirkungen der Behandlung. Ziel ist es, die Kommunikation zwischen Gesundheitsdienstleistern und Patienten zu verbessern, da Patienten möglicherweise zögern, Behandlungsschwierigkeiten zu besprechen.
Entwickelt mit Input von Patientenorganisationen wie der Acromegaly Community zielt ACRO/TRUTH darauf ab, Patienten zu ermächtigen und Behandlungspläne zu optimieren. Die Initiative wird auf zusätzliche Bildungsangebote, einschließlich einer Sprecherplattform, ausgeweitet.
- Launch of ACRO/TRUTH educational initiative to raise awareness of acromegaly treatment challenges
- Collaboration with patient organizations like Acromegaly Community to develop the initiative
- Potential for improved patient-doctor communication and treatment optimization
- None.
The launch of ACRO/TRUTH by Crinetics Pharmaceuticals is a strategic move to address the unmet needs in acromegaly treatment. While not directly impacting financials, this initiative could enhance Crinetics' reputation and potentially drive future product adoption.
The focus on patient perspectives and peer-reviewed data highlights the limitations of current injectable treatments, setting the stage for Crinetics' potential oral therapies. This educational effort could create demand for alternative treatments, aligning with Crinetics' pipeline.
Investors should note that this initiative may position Crinetics as a thought leader in acromegaly treatment, potentially strengthening relationships with healthcare providers and patients. However, the direct financial impact is likely minimal in the short term.
The ACRO/TRUTH initiative represents a savvy market positioning strategy for Crinetics. By highlighting the challenges with current acromegaly treatments, they're priming the market for their innovative solutions.
This approach could accelerate market acceptance of Crinetics' potential future products, particularly if they offer improvements over injectable SRLs. The collaboration with patient organizations like Acromegaly Community adds credibility and reach to their efforts.
While not immediately revenue-generating, this initiative could build brand equity and foster loyalty among healthcare providers and patients. Long-term, this could translate into faster adoption rates and market share gains if Crinetics successfully brings new acromegaly treatments to market.
ACRO/TRUTH Provides Authentic Patient Perspectives, Peer-Reviewed Data on Treatment-Related Symptoms, Side Effects and Quality-of-Life Impact of Current Acromegaly Standard-of-Care
SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the launch of the ACRO/TRUTH healthcare provider (HCP) educational website and initiative, the purpose of which is to spotlight the significant challenges and burdens many people living with acromegaly experience when managing their disease with the current standard-of-care, injectable somatostatin receptor ligands (SRLs).
“People living with acromegaly still experience diminished quality of life due to their disease and to the limitations of the treatment options currently available to treat their disease,” said Alan Krasner, M.D., Chief Endocrinologist at Crinetics. “Crinetics is dedicated to bringing forward innovative products to better the lives of patients, and an integral part of that mission is bringing the patient perspective to the forefront.”
The initiative will be anchored with a dynamic website that puts the patient perspective front-and-center through authentic video storytelling, together with peer-reviewed data published by endocrinologists specializing in acromegaly. Topics include details on the incidence and significance of breakthrough symptoms, injection site reactions, common side effects, and the emotional impact associated with treatment. HCPs can also sign up to stay informed on the latest clinical insights and research.
ACRO/TRUTH was informed by numerous interviews with people living with acromegaly and endocrinologists, in addition to published research on the impact of current treatments on patients' lives. The initiative will expand to include additional online and offline educational offerings, such as a speaker’s panel.
Research has shown interactions between HCPs and people living with acromegaly can be impacted by the protracted path to diagnosis and a general lack of information about the disease in the health care community.1 In turn, people living with acromegaly can be hesitant to discuss the challenges they face while on a prescribed treatment.1 To help elevate the voices of the patient community, ACRO/TRUTH was created with extensive input from leading patient organizations like Acromegaly Community.
“While diagnosis is the first step to getting better when living with acromegaly, it is critical to empower patients to be active partners in their care journeys immediately following that diagnosis,” said Jill Sisco, president of Acromegaly Community. “Once on a treatment, disease and symptom management can still be challenging for both patients and their healthcare providers. ACRO/TRUTH is an innovative, first-of-its-kind initiative that can lead to an informed conversation between healthcare providers and people living with acromegaly, to ensure treatment plans are optimized to enable productive lives.”
To learn more, visit AcromegalyTruth.com.
ABOUT ACROMEGALY
Acromegaly is a serious rare disease generally caused by a pituitary adenoma, a benign tumor in the pituitary that secretes growth hormone (GH). Excess GH secretion causes excess secretion of IGF-1 from the liver. Prolonged exposure to increased levels of IGF-1 and GH leads to progressive and serious systemic complications, often resulting in bone, joint, cardiovascular, metabolic, cerebrovascular, or respiratory disease. Acromegaly symptoms include headache, joint aches, fatigue, sleep apnea, severe sweating, hyperhidrosis/oily skin, bone and cartilage overgrowth, abnormal growth of hands and feet, enlargement of heart, liver, and other organs and alteration of facial features. Uncontrolled acromegaly results in increased mortality and has a debilitating impact on daily functioning and quality of life.
Surgical removal of pituitary adenomas, if possible, is the preferred initial treatment for most acromegaly patients. Pharmacotherapy is used for patients who are not candidates for surgery, or when surgery is unsuccessful in achieving treatment goals. Approximately
ABOUT CRINETICS PHARMACEUTICALS
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics’ lead development candidate, paltusotine, is an investigational, first-in-class, oral, once-daily somatostatin receptor type 2 (SST2) agonist in Phase 3 clinical development for acromegaly and in Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics is also developing atumelnant (CRN04894), an investigational, first-in-class, oral ACTH antagonist, that is currently completing Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing’s disease. All of the company’s drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements including statements regarding the plans for the clinical development of atumelnant and paltusotine, including the therapeutic potential and clinical benefits or safety profile thereof. These forward-looking statements speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions, including, without limitation, the risks and uncertainties described in the Company’s periodic filings with the Securities and Exchange Commission (“SEC”). The events and circumstances reflected in the Company’s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Additional information on risks facing Crinetics can be found under the heading “Risk Factors” in Crinetics’ periodic filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2023 and quarterly report on Form 10-Q for the quarter ended June 30, 2024. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by applicable law, Crinetics does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Investors:
Gayathri Diwakar
Head of Investor Relations
gdiwakar@crinetics.com
(858) 345-6340
Media:
Natalie Badillo
Head of Corporate Communications
nbadillo@crinetics.com
(858) 345-6075
Reference
_____________________________
1 Gurel MH, Bruening PR, Rhodes C, Lomax KG. Patient perspectives on the impact of acromegaly: results from individual and group interviews. Patient Prefer Adherence. 2014;8:53-62. doi:10.2147/PPA.S56740
FAQ
What is the purpose of Crinetics' ACRO/TRUTH initiative for acromegaly (CRNX)?
What features does the ACRO/TRUTH website offer for acromegaly education (CRNX)?
How does ACRO/TRUTH aim to improve acromegaly patient care (CRNX)?
What future plans does Crinetics have for the ACRO/TRUTH acromegaly initiative (CRNX)?
